Active	Status	Sponsor type	Region	Phase	Filter
6 Active 11 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Perin, Emerson
ACORD, NCT00117936: Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease	Not yet recruiting	2	150	NA	Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo	CardioVascular BioTherapeutics, Inc.	Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis	03/22	03/23
CATO, NCT06145035: Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy	Recruiting	2	60	US	umbilical cord-derived mesenchymal stromal cells (UC-MSCs)	Roberto Bolli, University of Miami, University of Texas, United States Department of Defense	Ischemic Heart Disease	01/26	01/26
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Active, not recruiting	2	456	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	01/25	01/25
DCMII, NCT04476901: Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy	Recruiting	2	136	US	allogeneic human mesenchymal stem cells (hMSCs), Placebo	Joshua M Hare, United States Department of Defense, The University of Texas Health Science Center, Houston	Non-ischemic Dilated Cardiomyopathy	12/25	12/25
NCT00314366: Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)	Completed	1	21	US	Stem Cell Therapy, NOGA Myostar catheter, Control (plasma)	Texas Heart Institute, CHI St. Luke's Health, Texas, Aldagen	Coronary Artery Disease	08/09	08/23
COSIRA-II, NCT05102019: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II	Recruiting	N/A	380	Canada, US	Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry	Neovasc Inc., Shockwave Medical, Inc.	Refractory Angina	06/25	12/28